Allosteric inhibition of HIV-1 integrase activity

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 339-345

  Engelman, Alan ^a   Kessl, Jacques J ^b   Kvaratskhelia, Mamuka ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HIV 1 INTEGRASE; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ALLOSTERISM; DOSE RESPONSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; EX VIVO STUDY; PROTEIN MULTIMERIZATION; REVIEW;

ALLOSTERIC REGULATION; CATALYTIC DOMAIN; CYTOPLASM; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878869428     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.04.010     Document Type: Review

References (41)

1. Engelman A., Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 2012, 10:279-290.
2. Frentz D., Boucher C.A., van de Vijver D.A. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012, 14:17-27.
3. Krishnan L., Engelman A. Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem 2012, 287:40858-40866.
4. Nguyen B.Y., Isaacs R.D., Teppler H., Leavitt R.Y., Sklar P., Iwamoto M., Wenning L.A., Miller M.D., Chen J., Kemp R., et al. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 2011, 1222:83-89.
5. Quashie P.K., Mesplède T., Wainberg M.A. Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis 2013, 26:43-49.
6. Al-Mawsawi L.Q., Neamati N. Allosteric inhibitor development targeting HIV-1 integrase. ChemMedChem 2011, 6:228-241.
7. Masuda T. Non-enzymatic functions of retroviral integrase: the next target for novel anti-HIV drug development. Front Microbiol 2011, 2:210.
8. Quashie P.K., Sloan R.D., Wainberg M.A. Novel therapeutic strategies targeting HIV integrase. BMC Med 2012, 10:34.
9. Craigie R., Bushman F.D. HIV DNA integration. Cold Spring Harb Perspect Med 2012, 2:a006890.
10. Cherepanov P., Devroe E., Silver P.A., Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem 2004, 279:48883-48892.
11. Wang H., Jurado K.A., Wu X., Shun M.-C., Li X., Ferris A.L., Smith S.J., Patel P.A., Fuchs J.R., Cherepanov P., et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res 2012, 40:11518-11530.
12. Schrijvers R., Vets S., De Rijck J., Malani N., Bushman F.D., Debyser Z., Gijsbers R. HRP-2 determines HIV-1 integration site selection in LEDGF/p75 depleted cells. Retrovirology 2012, 9:84.
13. Ocwieja K.E., Brady T.L., Ronen K., Huegel A., Roth S.L., Schaller T., James L.C., Towers G.J., Young J.A., Chanda S.K., et al. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog 2011, 7:e1001313.
14. Koh Y., Wu X., Ferris A.L., Matreyek K.A., Smith S.J., Lee K., KewalRamani V.N., Hughes S.H., Engelman A. Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration. J Virol 2013, 87:648-658.
15. Li X., Krishnan L., Cherepanov P., Engelman A. Structural biology of retroviral DNA integration. Virology 2011, 411:194-205.
16. Hare S., Maertens G.N. Cherepanov P: 3'-processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J 2012, 31:3020-3028.
17. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.
18. Maertens G.N., Hare S., Cherepanov P. The mechanism of retroviral integration through X-ray structures of its key intermediates. Nature 2010, 468:326-329.
19. Krishnan L., Li X., Naraharisetty H.L., Hare S., Cherepanov P., Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A 2010, 107:15010-15915.
20. Kessl J.J., Li M., Ignatov M., Shkriabai N., Eidahl J.O., Feng L., Musier-Forsyth K., Craigie R., Kvaratskhelia M. FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75. Nucleic Acids Res 2011, 39:9009-9022.
21. Gupta K., Curtis J.E., Krueger S., Hwang Y., Cherepanov P., Bushman F.D., Van Duyne G.D. Solution conformations of prototype foamy virus integrase and its stable synaptic complex with u5 viral DNA. Structure 2012, 20:1918-1928.
22. Cherepanov P., Ambrosio A.L.B., Rahman S., Ellenberger T., Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A 2005, 102:17308-17313.
23. Raghavendra N.K., Engelman A. LEDGF/p75 interferes with the formation of synaptic nucleoprotein complexes that catalyze full-site HIV-1 DNA integration in vitro: implications for the mechanism of viral cDNA integration. Virology 2007, 360:1-5.
24. McKee C.J., Kessl J.J., Shkriabai N., Dar M.J., Engelman A., Kvaratskhelia M. Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. J Biol Chem 2008, 283:31802-31812.
25. Hare S., Di Nunzio F., Labeja A., Wang J., Engelman A., Cherepanov P. Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog 2009, 5:e1000515.
26. De Rijck J., Vandekerckhove L., Gijsbers R., Hombrouck A., Hendrix J., Vercammen J., Engelborghs Y., Christ F., Debyser Z. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 2006, 80:11498-11509.
27. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., Teo W., Poeschla E.M. An essential role for LEDGF/p75 in HIV integration. Science 2006, 314:461-464.
28. Cherepanov P., Sun Z.-Y.J., Rahman S., Maertens G., Wagner G., Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol 2005, 12:526-532.
29. Hayouka Z., Rosenbluh J., Levin A., Loya S., Lebendiker M., Veprintsev D., Kotler M., Hizi A., Loyter A., Friedler A. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc Natl Acad Sci U S A 2007, 104:8316-8321.
30. Al-Mawsawi L.Q., Christ F., Dayam R., Debyser Z., Neamati N. Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis. FEBS Lett 2008, 582:1425-1430.
31. Christ F., Voet A., Marchand A., Nicolet S., Desimmie B.A., Marchand D., Bardiot D., Van der Veken N.J., Van Remoortel B., Strelkov S.V., et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010, 6:442-448.
32. Fenwick C.W., Tremblay S., Wardrop E., Bethell R., Coulomb R., Elston R., Faucher A.-M., Mason S., Simoneau B., Tsantrizos Y., et al. Resistance studies with HIV-1 non-catalytic site integrase inhibitors. Antiviral Ther 2011, 16(Suppl 1):A9.
33. Tsiang M., Jones G.S., Niedziela-Majka A., Kan E., Lansdon E.B., Huang W., Hung M., Samuel D., Novikov N., Xu Y., et al. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 2012, 287:21189-21203.
34. Christ F., Shaw S., Demeulemeester J., Desimmie B.A., Marchand A., Butler S., Smets W., Chaltin P., Westby M., Debyser Z., et al. Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 2012, 56:4365-4374.
35. Kessl J.J., Jena N., Koh Y., Taskent-Sezgin H., Slaughter A., Feng L., de Silva S., Wu L., Le Grice S.F.J., Engelman A., et al. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2012, 287:16801-16811.
36. Shen L., Peterson S., Sedaghat A.R., McMahon M.A., Callender M., Zhang H., Zhou Y., Pitt E., Anderson K.S., Acosta E.P., et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008, 14:762-766.
37. Schrijvers R., De Rijck J., Demeulemeester J., Adachi N., Vets S., Ronen K., Christ F., Bushman F.D., Debyser Z., Gijsbers R. LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog 2012, 8:e1002558.
38. Kessl J.J., Eidahl J.O., Shkriabai N., Zhao Z., McKee C.J., Hess S., Burke T.R., Kvaratskhelia M. An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule. Mol Pharmacol 2009, 76:824-832.
39. Maroun R.G., Gayet S., Benleulmi M.S., Porumb H., Zargarian L., Merad H., Leh H., Mouscadet J.F., Troalen F., Fermandjian S. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 2001, 40:13840-13848.
40. Tintori C., Demeulemeester J., Franchi L., Massa S., Debyser Z., Christ F., Botta M. Discovery of small molecule HIV-1 integrase dimerization inhibitors. Bioorg Med Chem Lett 2012, 22:3109-3114.
41. Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, Koh Y, Wang W, Ballandras-Colas A, Pater PA, Fuchs JR, et al.: Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A 2013, . doi:10.1073/pnas.1300703110.